Sudden Cardiac Death in Infiltrative Cardiomyopathies: Sarcoidosis, Scleroderma, Amyloidosis, Hemachromatosis

Progress in Cardiovascular Diseases

Volumn 51, Issue 1, 2008, Pages 58-73

  Lubitz, Steven A ^a   Goldbarg, Seth H ^a   Mehta, Davendra ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIFIBROTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; ENDOTHELIN RECEPTOR ANTAGONIST; PROSTANOID;

ANTICOAGULATION; ATRIOVENTRICULAR BLOCK; CARDIOMYOPATHY; CLINICAL FEATURE; DEFIBRILLATOR; ELECTROCARDIOGRAM; HEART AMYLOIDOSIS; HEART DISEASE; HEART SARCOIDOSIS; HEART SCLERODERMA; HEMOCHROMATOSIS; PHLEBOTOMY; PROGNOSIS; REVIEW; STRATIFICATION; SUDDEN DEATH;

AMYLOIDOSIS; CARDIOMYOPATHIES; DEATH, SUDDEN, CARDIAC; HEMOCHROMATOSIS; HUMANS; SARCOIDOSIS; SCLERODERMA, SYSTEMIC;

EID: 46949111217     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2007.10.003     Document Type: Review

References (125)

1. Judson M.A., Baughman R.P., Teirstein A.S., et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16 (1999) 75-86
2. Rybicki B.A., Hirst K., Iyengar S.K., et al. A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) study. Sarcoidosis Vasc Diffuse Lung Dis 22 (2005) 115-122
3. Bernstein M., Konzlemann F.W., and Sidlick D.M. Boeck's sarcoid: report of a case with visceral involvement. Arch Intern Med 44 (1929) 721-734
4. Roberts W.C., McAllister Jr. H.A., and Ferrans V.J. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 63 (1977) 86-108
5. Mitchell D.N., du Bois R.M., and Oldershaw P.J. Cardiac sarcoidosis. BMJ 314 (1997) 320-321
6. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48 (2006) e247-e346
7. Rybicki B.A., and Iannuzzi M.C. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med 28 (2007) 22-35
8. Rossman M.D., Thompson B., Frederick M., et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 73 (2003) 720-735
9. Rybicki B.A., Iannuzzi M.C., Frederick M.M., et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 164 (2001) 2085-2091
10. Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164 (2001) 1885-1889
11. Silverman K.J., Hutchins G.M., and Bulkley B.H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58 (1978) 1204-1211
12. Sekiguchi M., Numao Y., and Imai M. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. I. Sarcoidosis. Jpn Circ J 44 (1980) 249-263
13. Matsui Y., Iwai K., Tachibana T., et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci 278 (1976) 455-469
14. Fleming H.A. Sarcoid heart disease: a review and an appeal. Thorax 35 (1980) 641-643
15. Fleming H.A., and Bailey S.M. The prognosis of sarcoid heart disease in the United Kingdom. Ann N Y Acad Sci 465 (1986) 543-550
16. Valantine H., McKenna W.J., Nihoyannopoulos P., et al. Sarcoidosis: a pattern of clinical and morphological presentation. Br Heart J 57 (1987) 256-263
17. Yager J.E., Hernandez A.F., Steenbergen C., et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant 24 (2005) 1988-1990
18. Yazaki Y., Isobe M., Hiroe M., et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88 (2001) 1006-1010
19. Koplan B.A., Soejima K., Baughman K., et al. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm 3 (2006) 924-929
20. Ott P., Marcus F.I., Sobonya R.E., et al. Cardiac sarcoidosis masquerading as right ventricular dysplasia. Pacing Clin Electrophysiol 26 (2003) 1498-1503
21. Furushima H., Chinushi M., Sugiura H., et al. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin Cardiol 27 (2004) 217-222
22. Siltzbach L.E. The Kveim test in sarcoidosis. A study of 750 patients. JAMA 178 (1961) 476-482
23. Ardehali H., Howard D.L., Hariri A., et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 150 (2005) 459-463
24. Doughan A.R., and Williams B.R. Cardiac sarcoidosis. Heart 92 (2006) 282-288
25. Stein E., Jackler I., Stimmel B., et al. Asymptomatic electrocardiographic alterations in sarcoidosis. Am Heart J 86 (1973) 474-477
26. Hiraga H., Yuwai K., Hiroe M., et al. Guidelines for the diagnosis of cardiac sarcoidosis: Study Report of Diffuse Pulmonary Diseases. Jpn Minist Health Welf (1993) 23-24
27. Ishimaru S., Tsujino I., Takei T., et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26 (2005) 1538-1543
28. Yamagishi H., Shirai N., Takagi M., et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 44 (2003) 1030-1036
29. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 (2005) 1683-1690
30. Vignaux O., Dhote R., Duboc D., et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 122 (2002) 1895-1901
31. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 128 (2005) 30-35
32. Aizer A., Stern E.H., Gomes J.A., et al. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol 96 (2005) 276-282
33. Yasutake H., Seino Y., Kashiwagi M., et al. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol 102 (2005) 259-268
34. Uslu N., Akyol A., Gorgulu S., et al. Heart rate variability in patients with systemic sarcoidosis. Ann Noninvasive Electrocardiol 11 (2006) 38-42
35. Uyarel H., Uslu N., Okmen E., et al. QT dispersion in sarcoidosis. Chest 128 (2005) 2619-2625
36. Yodogawa K., Seino Y., Ohara T., et al. Non-invasive detection of latent cardiac conduction abnormalities in patients with pulmonary sarcoidosis. Circ J 71 (2007) 540-545
37. Winters S.L., Cohen M., Greenberg S., et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 18 (1991) 937-943
38. Kato Y., Morimoto S., Uemura A., et al. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 20 (2003) 133-137
39. Gregoratos G., Abrams J., Epstein A.E., et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Cardiovasc Electrophysiol 13 (2002) 1183-1199
40. Takada K., Ina Y., Yamamoto M., et al. Prognosis after pacemaker implantation in cardiac sarcoidosis in Japan. Clinical evaluation of corticosteroid therapy. Sarcoidosis 11 (1994) 113-117
41. Zaidi A.R., Zaidi A., and Vaitkus P.T. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant 26 (2007) 714-717
42. Gilliland B.C. Systemic sclerosis (Scleroderma) and related disorders. In: Kasper D.L., Braunwald E., Fauci A.S., Hauser S.L., Longo D.L., and Jameson J.L. (Eds). Harrison's principles of internal medicine. 16th ed. (2005), McGraw-Hill, New York 1979-1990
43. Fonseca C., Lindahl G.E., Ponticos M., et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 357 (2007) 1210-1220
44. Lawrence R.C., Helmick C.G., Arnett F.C., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41 (1998) 778-799
45. Lee P., Langevitz P., Alderdice C.A., et al. Mortality in systemic sclerosis (scleroderma). Q J Med 82 (1992) 139-148
46. D'Angelo W.A., Fries J.F., Masi A.T., et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46 (1969) 428-440
47. Byers R.J., Marshall D.A., and Freemont A.J. Pericardial involvement in systemic sclerosis. Ann Rheum Dis 56 (1997) 393-394
48. Ridolfi R.L., Bulkley B.H., and Hutchins G.M. The cardiac conduction system in progressive systemic sclerosis. Clinical and pathologic features of 35 patients. Am J Med 61 (1976) 361-366
49. Bulkley B.H., Ridolfi R.L., Salyer W.R., et al. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation 53 (1976) 483-490
50. Sackner M.A., Heinz E.R., and Steinberg A.J. The heart in scleroderma. Am J Cardiol 17 (1966) 542-559
51. Roberts N.K., and Cabeen W.R. Atrioventricular nodal function in progressive systemic sclerosis: electrophysiological and morphological findings. Br Heart J 44 (1980) 529-533
52. Janosik D.L., Osborn T.G., Moore T.L., et al. Heart disease in systemic sclerosis. Semin Arthritis Rheum 19 (1989) 191-200
53. Bulkley B.H., Klacsmann P.G., and Hutchins G.M. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J 95 (1978) 563-569
54. Windesheim J.H., and Parkin T.W. Electrocardiograms of ninety patients with acrosclerosis and progressive diffuse sclerosis (scleroderma). Circulation 17 (1958) 874-881
55. Follansbee W.P., Curtiss E.I., Rahko P.S., et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am J Med 79 (1985) 183-192
56. Kostis J.B., Seibold J.R., Turkevich D., et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 84 (1988) 1007-1015
57. Clements P.J., Furst D.E., Cabeen W., et al. The relationship arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS). Am J Med 71 (1981) 38-46
58. Oram S., and Stokes W. The heart in scleroderma. Br Heart J 23 (1961) 243-259
59. Paradiso M., Gabrielli F., Coppotelli L., et al. Signal-averaged electrocardiography and echocardiography in the evaluation of myocardial involvement in progressive systemic sclerosis. Int J Cardiol 53 (1996) 171-177
60. Morelli S., Sgreccia A., De Marzio P., et al. Noninvasive assessment of myocardial involvement in patients with systemic sclerosis: role of signal averaged electrocardiography. J Rheumatol 24 (1997) 2358-2363
61. Paradiso M., Di Franco M., Musca A., et al. Ventricular late potentials in systemic sclerosis: relationship with skin involvement. J Rheumatol 29 (2002) 1388-1392
62. Pancera P., Sansone S., Presciuttini B., et al. Autonomic nervous system dysfunction in sclerodermic and primary Raynaud's phenomenon. Clin Sci (Lond) 96 (1999) 49-57
63. Di Franco M., Paradiso M., Riccieri V., et al. Autonomic dysfunction and microvascular damage in systemic sclerosis. Clin Rheumatol 26 (2007) 1278-1283
64. Morelli S., Piccirillo G., Fimognari F., et al. Twenty-four hour heart period variability in systemic sclerosis. J Rheumatol 23 (1996) 643-645
65. Sgreccia A., Morelli S., Ferrante L., et al. QT interval and QT dispersion in systemic sclerosis (scleroderma). J Intern Med 243 (1998) 127-132
66. Gaal J., Hegedus I., Devenyi K., et al. Myocardial gallium-67 citrate scintigraphy in patients with systemic sclerosis. Ann Rheum Dis 54 (1995) 856-858
67. Plastiras S.C., Kelekis N., and Tzelepis G.E. Magnetic resonance imaging for the detection of myocardial fibrosis in scleroderma. N Engl J Med 354 (2006) 2194-2196
68. Ferri C., Giuggioli D., Sebastiani M., et al. Heart involvement and systemic sclerosis. Lupus 14 (2005) 702-707
69. Ferri C., Emdin M., Nielsen H., et al. Assessment of heart involvement. Clin Exp Rheumatol 21 (2003) S24-S28
70. Bennett R., Bluestone R., Holt P.J., et al. Survival in scleroderma. Ann Rheum Dis 30 (1971) 581-588
71. Ferri C., Bernini L., Bongiorni M.G., et al. Noninvasive evaluation of cardiac dysrhythmias, and their relationship with multisystemic symptoms, in progressive systemic sclerosis patients. Arthritis Rheum 28 (1985) 1259-1266
72. Rokas S., Mavrikakis M., Agrios N., et al. Electrophysiologic abnormalities of cardiac function in progressive systemic sclerosis. J Electrocardiol 29 (1996) 17-25
73. Paulisinski R., Chibowska M., Bilan A., et al. Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): electrocardiographic substudy-three months follow-up. Adv Exp Med Biol 455 (1999) 295-298
74. Lacroix D., Brigadeau F., Marquie C., et al. Electroanatomic mapping and ablation of ventricular tachycardia associated with systemic sclerosis. Europace 6 (2004) 336-342
75. Martinez-Taboada V., Olalla J., Blanco R., et al. Malignant ventricular arrhythmia in systemic sclerosis controlled with an implantable cardioverter defibrillator. J Rheumatol 21 (1994) 2166-2167
76. Kyle R.A., Linos A., Beard C.M., et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79 (1992) 1817-1822
77. Shah K.B., Inoue Y., and Mehra M.R. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 166 (2006) 1805-1813
78. Falk R.H. Diagnosis and management of the cardiac amyloidoses. Circulation 112 (2005) 2047-2060
79. Connors L.H., Richardson A.M., Theberge R., et al. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid 7 (2000) 54-69
80. Dubrey S.W., Cha K., Simms R.W., et al. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 77 (1996) 313-315
81. Smith T.J., Kyle R.A., and Lie J.T. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc 59 (1984) 547-555
82. James T.N. Pathology of the cardiac conduction system in amyloidosis. Ann Intern Med 65 (1966) 28-36
83. Mueller P.S., Edwards W.D., and Gertz M.A. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 109 (2000) 181-188
84. Cantwell R.V., Aviles R.J., Bjornsson J., et al. Cardiac amyloidosis presenting with elevations of cardiac troponin I and angina pectoris. Clin Cardiol 25 (2002) 33-37
85. Dispenzieri A., Kyle R.A., Gertz M.A., et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361 (2003) 1787-1789
86. Chamarthi B., Dubrey S.W., Cha K., et al. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol 80 (1997) 1242-1245
87. Murtagh B., Hammill S.C., Gertz M.A., et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 95 (2005) 535-537
88. Dubrey S.W., Cha K., Anderson J., et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91 (1998) 141-157
89. Siqueira-Filho A.G., Cunha C.L., Tajik A.J., et al. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 63 (1981) 188-196
90. Cueto-Garcia L., Reeder G.S., Kyle R.A., et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 6 (1985) 737-743
91. Klein A.L., Hatle L.K., Taliercio C.P., et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16 (1990) 1135-1141
92. Koyama J., Ray-Sequin P.A., and Falk R.H. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107 (2003) 2446-2452
93. Maceira A.M., Joshi J., Prasad S.K., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 (2005) 186-193
94. Ardehali H., Qasim A., Cappola T., et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 147 (2004) 919-923
95. Falk R.H., Rubinow A., and Cohen A.S. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 3 (1984) 107-113
96. Palladini G., Malamani G., Co F., et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 24 (2001) 1228-1233
97. Dubrey S.W., Bilazarian S., LaValley M., et al. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J 134 (1997) 994-1001
98. Reisinger J., Dubrey S.W., Lavalley M., et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol 30 (1997) 1046-1051
99. Gertz M.A., Falk R.H., Skinner M., et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 55 (1985) 1645
100. Rubinow A., Skinner M., and Cohen A.S. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 63 (1981) 1285-1288
101. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140 (2004) 85-93
102. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13 (1996) 399-408
103. Girelli D., Bozzini C., Roetto A., et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 122 (2002) 1295-1302
104. Lamon J.M., Marynick S.P., Roseblatt R., et al. Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people. Gastroenterology 76 (1979) 178-183
105. Merryweather-Clarke A.T., Pointon J.J., Shearman J.D., et al. Global prevalence of putative haemochromatosis mutations. J Med Genet 34 (1997) 275-278
106. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 350 (2004) 2383-2397
107. Rochette J., Pointon J.J., Fisher C.A., et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet 64 (1999) 1056-1062
108. Easley Jr. R.M., Schreiner Jr. B.F., and Yu P.N. Reversible cardiomyopathy associated with hemochromatosis. N Engl J Med 287 (1972) 866-867
109. Buja L.M., and Roberts W.C. Iron in the heart. Etiology and clinical significance. Am J Med 51 (1971) 209-221
110. Vigorita V.J., and Hutchins G.M. Cardiac conduction system in hemochromatosis: clinical and pathologic features of six patients. Am J Cardiol 44 (1979) 418-423
111. Tuomainen T.P., Kontula K., Nyyssonen K., et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. Circulation 100 (1999) 1274-1279
112. Ellervik C., Tybjaerg-Hansen A., Grande P., et al. Hereditary hemochromatosis and risk of ischemic heart disease: a prospective study and a case-control study. Circulation 112 (2005) 185-193
113. Palka P., Macdonald G., Lange A., et al. The role of Doppler left ventricular filling indexes and Doppler tissue echocardiography in the assessment of cardiac involvement in hereditary hemochromatosis. J Am Soc Echocardiogr 15 (2002) 884-890
114. Shizukuda Y., Bolan C.D., Tripodi D.J., et al. Left ventricular systolic function during stress echocardiography exercise in subjects with asymptomatic hereditary hemochromatosis. Am J Cardiol 98 (2006) 694-698
115. Cecchetti G., Binda A., Piperno A., et al. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation. Eur Heart J 12 (1991) 224-230
116. Waxman S., Eustace S., and Hartnell G.G. Myocardial involvement in primary hemochromatosis demonstrated by magnetic resonance imaging. Am Heart J 128 (1994) 1047-1049
117. Ptaszek L.M., Price E.T., Hu M.Y., et al. Early diagnosis of hemochromatosis-related cardiomyopathy with magnetic resonance imaging. J Cardiovasc Magn Reson 7 (2005) 689-692
118. Roest M., van der Schouw Y.T., de Valk B., et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 100 (1999) 1268-1273
119. Strobel J.S., Fuisz A.R., Epstein A.E., et al. Syncope and inducible ventricular fibrillation in a woman with hemochromatosis. J Interv Card Electrophysiol 3 (1999) 225-229
120. Luis Morinigo J., Martin Luengo C., Ledesma C., et al. Ventricular tachycardia and cardiac hemochromatosis. Rev Esp Cardiol 54 (2001) 1328-1331
121. Lemery R., Brugada P., Havenith M., et al. Sudden death in hemochromatosis after closed-chest catheter ablation of the atrioventricular junction. Am J Cardiol 61 (1988) 941-943
122. Yalcinkaya S., Kumbasar S.D., Semiz E., et al. Sustained ventricular tachycardia in cardiac hemochromatosis treated with amiodarone. J Electrocardiol 30 (1997) 147-149
123. Durand E., Grinda J.M., and Bruneval P. Cardiogenic shock in a young woman revealing juvenile haemochromatosis. Heart 89 (2003) 870
124. Dabestani A., Child J.S., Henze E., et al. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. Am J Cardiol 54 (1984) 153-159
125. Rivers J., Garrahy P., Robinson W., et al. Reversible cardiac dysfunction in hemochromatosis. Am Heart J 113 (1987) 216-217